<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01045109</url>
  </required_header>
  <id_info>
    <org_study_id>CTRF #P-06-068</org_study_id>
    <secondary_id>CTO# 101121</secondary_id>
    <secondary_id>MUSC HR# 17398</secondary_id>
    <secondary_id>MUSC CTRC #790</secondary_id>
    <nct_id>NCT01045109</nct_id>
  </id_info>
  <brief_title>Vitamin D3 Supplementation in Participants Diagnosed With Early-Stage Prostate Cancer Who Decide to Undergo Active Surveillance Treatment Regimen.</brief_title>
  <acronym>D3/PCa</acronym>
  <official_title>Vitamin D and Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial is aimed at measuring the effect of vitamin D3 supplementation on serum
      prostate-specific antigen (PSA) levels in patients diagnosed with early stage, low-grade,
      low-risk prostate cancer (Gleason score less than/equal to 6; PSA less than/equal to 10;
      clinical stage T1C or T2a), who elect to have their disease monitored through active
      surveillance for at least one year.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of vitamin D3 supplementation on prostate specific antigen levels in patients diagnosed with early stage, low-grade, low-risk prostate cancer.</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of subjects (determined by safety lab values every 8 weeks: serum Creatinine, Ca, Phosphorus, PTH, vit D3; CBC with differential; and urine Ca/Creat ratio) taking vitamin D3 supplementation (4,000 I.U.) daily.</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>open-label vitamin D3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One arm: open-label receiving vitamin D3 4,000 IU daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>cholecalciferol</intervention_name>
    <description>4,000 I.U. softgel daily orally for 48 weeks</description>
    <arm_group_label>open-label vitamin D3</arm_group_label>
    <other_name>vitamin D3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>cholecalciferol</intervention_name>
    <description>cholecalciferol or vitamin D3 4,000 IU daily for 48 weeks</description>
    <arm_group_label>open-label vitamin D3</arm_group_label>
    <other_name>vitamin D3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  lowgrade prostate cancer

          -  serum PSA less than/equal to 10 ng/ml

          -  Gleason score less than/equal to 6

          -  referred from their treating physician with treatment plan of active surveillance for
             one year

          -  serum creatinine less than/equal to 2.0 mg/dL

          -  serum phosphate (measured as phosphorus)greater than 2.3 and less than 4.8 mg/dL

          -  serum calcium greater than 8.5 and less than 10.5 mg/dL

        Exclusion Criteria:

          -  concurrent malignancy, except non-melanoma skin cancer

          -  history of sarcoidosis

          -  history of high dose (greater than 1,000 IU daily) vitamin D3 supplementation

          -  history of hypercalcemia

          -  treatment with lithium medication
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sebastiano Gattoni-Celli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MUSC Department of Radiation Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.vitamindcouncil.org</url>
    <description>Research/findings related to vitamin D3</description>
  </link>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 2, 2008</study_first_submitted>
  <study_first_submitted_qc>January 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2010</study_first_posted>
  <last_update_submitted>August 4, 2011</last_update_submitted>
  <last_update_submitted_qc>August 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2011</last_update_posted>
  <responsible_party>
    <name_title>Sebastiano Gattoni-Celli, M.D.</name_title>
    <organization>MUSC Department of Radiation Oncology</organization>
  </responsible_party>
  <keyword>prostate</keyword>
  <keyword>cancer</keyword>
  <keyword>vitamin D3</keyword>
  <keyword>early stage</keyword>
  <keyword>active surveillance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

